A detailed history of Headlands Technologies LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Headlands Technologies LLC holds 4,371 shares of VRTX stock, worth $2.05 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
4,371
Previous 2,415 80.99%
Holding current value
$2.05 Million
Previous $1.01 Million 102.97%
% of portfolio
0.22%
Previous 0.25%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$392.81 - $485.53 $768,336 - $949,696
1,956 Added 80.99%
4,371 $2.05 Million
Q1 2024

May 07, 2024

SELL
$407.69 - $446.08 $935,240 - $1.02 Million
-2,294 Reduced 48.72%
2,415 $1.01 Million
Q4 2023

Feb 02, 2024

BUY
$343.0 - $410.68 $234,955 - $281,315
685 Added 17.02%
4,709 $1.92 Million
Q3 2023

Nov 09, 2023

BUY
$338.18 - $362.46 $1.36 Million - $1.46 Million
4,024 New
4,024 $1.4 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $422,924 - $475,790
1,480 New
1,480 $427,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.